Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.
Future Oncol
; 17(1): 103-115, 2021 Jan.
Article
in En
| MEDLINE
| ID: mdl-32959703
ABSTRACT
Background:
Five EGFR-tyrosine kinase inhibitors (EGFR TKIs) are currently available in the first-line setting for non-small-cell lung cancer (NSCLC) in Japan. The aim here was to compare the relative efficacy of EGFR TKIs in the Japanese population. Materials &methods:
A systematic review identified randomized controlled trials examining the efficacy of first-line EGFR TKIs. A Bayesian network meta-analysis was used to assess these EGFR TKI comparisons for progression-free survival (PFS).Results:
A total of seven randomized controlled trials were identified and considered for network meta-analysis. Dacomitinib showed a trend toward improved PFS versus all comparators.Conclusion:
Dacomitinib demonstrated a trend toward improved PFS and therefore, should be considered one of the standard first-line therapies for Japanese patients diagnosed with EGFR+ non-small-cell lung cancer.Key words
Full text:
1
Collection:
01-internacional
Health context:
6_ODS3_enfermedades_notrasmisibles
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
Lung Neoplasms
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
/
Systematic_reviews
Limits:
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Future Oncol
Year:
2021
Document type:
Article